Community Investing Ideas

Global Weekly Picks

CA$31.8
FV
98.8% undervalued intrinsic discount
544
users have viewed this narrative
6users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
AMD logo
Advanced Micro Devices

A formidable player in AI and enterprise computing.

1. Growth Engines in AI & Data Center AMD reported 36% YoY revenue growth in Q1 2025 , reaching $7.44B , with non‑GAAP EPS of $0.96 , a 55% YoY jump.Read more

View narrative
6.7k
users have viewed this narrative
13users have liked this narrative
6users have commented on this narrative
89users have followed this narrative
US$270
22.5% undervalued intrinsic discount
oscargarcia's Fair Value
Revenue
19.11% p.a.
Profit Margin
8.03%
Future PE
114.31x
Price in 2030
US$425.72
US$391.25
11.1% undervalued intrinsic discount
yiannisz's Fair Value
Revenue
8.23% p.a.
Profit Margin
30.01%
Future PE
19.67x
Price in 2030
US$590.45
US$66
184.5% overvalued intrinsic discount
yiannisz's Fair Value
Revenue
11.95% p.a.
Profit Margin
18.01%
Future PE
314.38x
Price in 2029
US$91.97
NOK 130
14.3% undervalued intrinsic discount
MrMoneyMan's Fair Value
Revenue
15.07% p.a.
Profit Margin
8.57%
Future PE
19.82x
Price in 2030
NOK 241.08
US$213.62
43.5% overvalued intrinsic discount
weldcoin's Fair Value
Revenue
10% p.a.
Profit Margin
33%
Future PE
25x
Price in 2028
US$338.39
TWLO logo
Twilio

Overvalued

Warren Buffett would likely not invest in Twilio Inc. at its current stage.Read more

View narrative
182
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$68
102.2% overvalued intrinsic discount
WBIN's Fair Value
Revenue
24.14% p.a.
Profit Margin
7.61%
Future PE
21.41x
Price in 2030
US$100.02
US$153.97
21.9% overvalued intrinsic discount
BlackGoat's Fair Value
Revenue
39% p.a.
Profit Margin
38%
Future PE
92x
Price in 2030
US$214.78
NVO logo
Novo Nordisk

Novo Nordisk will thrive with a 34.7751% profit margin boost

23-apr-2025 Novo Nordisk will face competition in the obisitas and diabetes space. Regulation and insurances may impact its growth.Read more

View narrative
126
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
US$65.5
25.3% undervalued intrinsic discount
Silvester's Fair Value
Revenue
15.81% p.a.
Profit Margin
34.78%
Future PE
17.14x
Price in 2030
US$126.83
US$279.41
24.7% overvalued intrinsic discount
Robbo's Fair Value
Revenue
2.9% p.a.
Profit Margin
19.83%
Future PE
17.57x
Price in 2030
US$414.73